{"disease":{"id":"measurable-disease","name":"measurable disease"},"drugs":{"marketed":[{"drug_id":"azd5363","indication_name":"Triple-negative breast cancer with disease progression on or after chemotherapy in the neoadjuvant or adjuvant setting and/or in patients with measurable disease by RECIST v1.1","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Azd5363","generic_name":"azd5363","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"AKT","drug_class":"phosphatidylinositol 3-kinase (PI3K) inhibitor","quality_score":25,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06000306","title":"MRD Monitoring by Digital Droplet PCR in the Early Period After Allo-HSCT to Predict Patients at High Risk of Relapse","phase":"","overall_status":"COMPLETED","enrollment_count":192,"lead_sponsor_name":"Zhejiang University","has_results":false},{"nct_id":"NCT07264010","title":"Sorafenib Combined With Venetoclax as Pre-emptive Therapy Strategy for MRD+ AML: a Prospective, Single-arm, Multicenter Clinical Study","phase":"PHASE2, PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":87,"lead_sponsor_name":"Nanfang Hospital, Southern Medical University","has_results":false},{"nct_id":"NCT06595966","title":"Exploratory Research on Constructing a Computational Biological Model Based on NGS for MRD After Breast Cancer Surgery","phase":"","overall_status":"RECRUITING","enrollment_count":80,"lead_sponsor_name":"Second Affiliated Hospital, School of Medicine, Zhejiang University","has_results":false},{"nct_id":"NCT01743482","title":"Pazopanib in Advanced and Cisplatin-resistant Germ Cell Tumors","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":43,"lead_sponsor_name":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","has_results":false},{"nct_id":"NCT05361057","title":"Efficacy of Venetoclax Based Regimen in Prevention Relapse of Consecutive MRD Positive AML Patients","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":20,"lead_sponsor_name":"Institute of Hematology & Blood Diseases Hospital, China","has_results":false},{"nct_id":"NCT07392970","title":"Motixafortide for MRD Sensitization in AML","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":10,"lead_sponsor_name":"Washington University School of Medicine","has_results":false},{"nct_id":"NCT04827745","title":"Blinatumomab for Treatment of R/R or MRD-positive CD19-Positive MPAL","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":2,"lead_sponsor_name":"University of Maryland, Baltimore","has_results":false},{"nct_id":"NCT07223606","title":"Fecal Microbiota Transplant for Neuroblastoma in a Single Patient","phase":"","overall_status":"NO_LONGER_AVAILABLE","enrollment_count":null,"lead_sponsor_name":"ProgenaBiome","has_results":false}],"total":8},"guidelines":[],"source":"Drug Landscape verified database"}